



Antibody Validation Webinar Series

WEBINAR 3: What's in a name? Finding the antibody for the job

Moderator: Dr. Simon Goodman, The Antibody Society

Speakers: **Dr. Jan Voskuil**, Aeonian Biotech, and **Professor Andy Chalmers**, University of Bath and CiteAb

First Webcast: December 4, 2019

Now available On Demand

## Questions and Answers from the live Webcast on December 4, 2019

Question	Answer
Which kind of proteins should we be	AC response: I think researchers should be careful with all their
more prudent about when making	selections, but it also depends how central the antibody is to the
selections?	project. The more central the more careful you need to be to validate
	the antibody and also look for other non-antibody ways to confirm
	the result.
	JV response: Certain membrane proteins and certain nuclear proteins
	have proven to be tough to raise good antibodies to. Also mucines
	and heavily glycosylated proteins.
Dr. Voskuil, is it possible to know the	For more information, please see
names of the 2 anti-HER2 that are	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3263426/.
cross-reactive to HER4?	The three diagnostics and "validated" products were PATHWAY®
	HER2, Oracle <sup>®</sup> HER2, and HercepTest <sup>™</sup> antibody. Only the last one
	was selective to HER2, while the other two were cross-reactive to HER4.
What is a generic workflow for	<b>AC response</b> : That is a great question and warrants an entire webinar
validation if an antibody does not	or two! My feeling is it will often vary depending on the
work?	lab/project/antibody. I think the pillars of antibody validation paper*
	by the international working group is a good starting point for
	approaches that can be used, and then it's about matching them to your situation.
	*Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E,
	Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T. A proposal for validation of antibodies.
	Nat Methods. 2016 Oct;13(10):823-7. doi: 10.1038/nmeth.3995.
	JV response: Always try to find a few different antibodies from
	different sources. Always first copy the results of the datasheet to
	make sure the antibody has not lost its integrity.
	<b>SG response</b> : It's tough, which is why we're doing this. Standardized technology and following the providers data sheets may help. We'll deal with that later in the series.